Baranwal, Anmol
Chhetri, Rakchha
Yeung, David
Clark, Matthew
Shah, Syed http://orcid.org/0000-0003-4992-934X
Litzow, Mark R. http://orcid.org/0000-0002-9816-6302
Hogan, William J. http://orcid.org/0000-0002-5841-4105
Mangaonkar, Abhishek http://orcid.org/0000-0003-2458-9887
Alkhateeb, Hassan B.
Singhal, Deepak
Cibich, Alia
Bardy, Peter
Kok, Chung H. http://orcid.org/0000-0002-3181-7852
Hiwase, Devendra K. http://orcid.org/0000-0002-6666-3056
Shah, Mithun Vinod http://orcid.org/0000-0002-5359-336X
Article History
Received: 1 December 2022
Revised: 16 March 2023
Accepted: 20 March 2023
First Online: 3 April 2023
Competing interests
: MRL—Research funding (AbbVie, Astellas, Amgen, Actinium, Pluristem), Advisory board (Jaz, Omeros), Data monitoring committee (BioSight); DY—Research funding from BMS and Novartis, Honoraria from Novartis, Pfizer, Amgen, and Takeda; DKH—Membership on an entity’s Board of Directors or advisory committees (AbbVie, Novartis); MVS—Research funding to the institution (Abbvie, Celgene, Astellas, and MRKR Therapeutics). The other authors declare no competing interests.